Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Billeci

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Blood|July 15, 2006
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cellsChingwei V Lee, Sarah G Hymowitz, Heidi J Wallweber, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2013
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agentMark Merchant, Xiaolei Ma, Henry R Maun, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Blood|July 15, 2006
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cellsChingwei V Lee, Sarah G Hymowitz, Heidi J Wallweber, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2013
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agentMark Merchant, Xiaolei Ma, Henry R Maun, et al.
Pageof 2